Expansion opportunities NeurAxis has been actively expanding payer coverage for PENFS with multiple new medical policies and coverage across several states, signaling growing reimbursement milieu that can be leveraged to accelerate adoption and reach additional health plans, hospital systems, and independent clinics.

Rising demand Recent press highlights record revenue growth in Q1 2026 and ongoing Q2 updates, indicating increasing market interest in neuromodulation therapies and IB-Stim, presenting a ripe entry point for partnerships with distributors, durable medical equipment providers, and care networks.

Policy rapidity Several insurer policy additions within short timeframes demonstrate a receptive regulatory and payer environment; this creates an opportunity to align product trials, outcomes data, and value demonstrations with payer liaisons to drive faster coverage decisions.

Clinical integration Focus on pediatric and adult chronic conditions suggests collaboration potential with hospital systems, pediatric centers, pain clinics, and rehabilitation networks seeking neuromodulation solutions to expand their care pathways and improve patient outcomes.

Financial momentum Strong growth signals and accessible financing actions such as preferred stock dividends imply healthy liquidity and investor interest, enabling co-marketing ventures, joint pricing pilots, and scalable deployment partnerships with early adopters and regional health networks.